Glaxosmithkline Share News (GSK)
GSK Share
GSK Share
GSK Share
GSK Share
GSK
GSK Share
GSK Level 2
GSK Live
GSK Broker
GSK Directors
GSK Financial
GSK
GSK Short
GSK
Last checked at -
* Q4 sales $15.08 bln vs poll average of $15.09 bln * Core EPS $1.20 vs $1.28 forecast in Reuters poll * Expects 2014 sales to grow in the low to mid-single digits * CEO wants portfolio review complete by summer * Proposes dividend of 2.45 Sfr per share, up 7 pct By
Read more* Release of Priorix-Tetra, Varilrix put on temporary hold * Follows quality issue with some batches made in Belgium * German doctors told to ration both chickenpox vaccines FRANKFURT/LONDON, Jan 28 (Reuters) - GlaxoSmithKline has stopped worldwide deliveries of two chickenpox
Read moreFRANKFURT, Jan 27 (Reuters) - German doctors have been told to ration two chickenpox vaccines for children after drugmaker GlaxoSmithKline stopped deliveries, saying production quality standards had not been met. Healthcare regulators have issued guidelines to physicians to deal with shorta
Read more(Adds detail from CHMP statement, analyst comments; updates share movement) By Vrinda Manocha Jan 24 (Reuters) - PTC Therapeutics Inc said its drug to treat a rare muscular disorder failed to win support for a conditional approval from a panel of the European Medicines Agency, sending
Read more* European Medicine Agency backs Bayer's Adempas * Also recommends marketing approval for GSK's Eperzan * Knocks back Teva's Nerventra and Novartis' serelaxin By Kate Kelland LONDON, Jan 24 (Reuters) - Europe's drugs regulator gave its backing on Friday for marketing appro
Read moreLONDON, Jan 24 (Reuters) - GlaxoSmithKline said on Friday European regulators had given the green light to its once-weekly diabetes drug albiglutide, which it is marketing as Eperzan. Albiglutide belongs to the same class of injectable GLP-1 drugs as Victoza from Novo Nordisk, as well as By
Read more
LONDON (Alliance News) - GlaxoSmithKline PLC said Friday that its Phase III study of the combination treatment of Tafinlar and Mekinist for the treatment of metastatic melenoma had reached its primary endpoint. The company said the response rate and interim overall survival results in the s
Read moreLONDON, Jan 24 (Reuters) - GlaxoSmithKline said on Friday the first of its phase three studies into the combination of Tafinlar and Mekinist to treat melanoma, the deadliest form of skin cancer, had met its main goal. The results, along with further data expected from the study, will increa
Read moreLONDON (Alliance News) - Bank of England Governor Mark Carney Friday signaled that rising productivity will now be the key factor that decides when the central bank will start to tighten monetary policy, and any tightening will be a slow, gradual process.
In a speech at the World Ec
LONDON, Jan 24 (Reuters) - European drugs regulators gave their backing on Friday for marketing authorisations to be granted for Bayer's drug Adempas, designed to treat pulmonary hypertension, and for GlaxoSmithKline's diabetes medicine Eperzan. The regulator also backed a new drug from Da
Read more
Drug maker GlaxoSmithKline said on Friday that the Committee for Medicinal Products for Human Use (CHMP) has recommended marketing authorisation for its albiglutide treatment for type 2 diabetes. The decision by the CHMO, which is part of the European Medicines Agency, was hailed by the company as
Read moreLONDON (Alliance News) - The following is a summary of top news stories Friday.
----------
COMPANIES
----------
Royal Mail PLC reported a 2% increase in like-for-like revenues for the first half of the year, driven by further growth in its
LONDON, Jan 24 (Reuters) - GlaxoSmithKline said on Friday European regulators had given the green light to its once-weekly diabetes drug albiglutide, which it is marketing as Eperzan. Albiglutide belongs to the same class of injectable GLP-1 drugs as Victoza, from Novo Nordisk, and Byetta a
Read moreLONDON (Alliance News) - Pharmaceuticals giant GlaxoSmithKline PLC said Friday that it had received a recommendation for marketing authorisation for its Eperzan treatment for type 2 diabetes from the European Medicines Agency's Committee for Medical Products for Human Use. The recommendatio
Read moreLONDON (Alliance News) - The following UK shares received analyst recommendations Friday morning:
----------
FTSE 100
----------
KEPLER CHEUVREUX STARTS BP WITH 'BUY' - PRICE TARGET 545 PENCE
----------
KEPLER CHEUVREUX STARTS BG GROUP WITH 'HOLD
Last checked at